DiNubile Nicholas
Orthopedics. 2018 Jul 1;41(4):200-207. doi: 10.3928/01477447-20180511-06. Epub 2018 May 18.
Glucosamine and chondroitin sulfate, alone or in combination, are used worldwide by individuals suffering from osteoarthritis pain. They are by prescription in some countries but are available as over-the-counter dietary supplements in other countries, such as the United States. The inconclusive results of the National Institutes of Health-sponsored Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) did little to clarify the efficacy of these agents. However, some newer studies have provided a better perspective on the potential benefits that they can offer. Because the 2 in combination showed a significant level of efficacy in the moderate-to-severe knee osteoarthritis subgroup of the GAIT, this review examines the randomized, controlled trials published from that time to the present. The findings of these studies are mixed, owing in some cases to the high rate of placebo response added to by the ethical incorporation of rescue analgesics into protocols designed to evaluate the slow-acting, subtle effects of glucosamine and chondroitin sulfate in combination. The strong influence of the placebo effect and confounding of results by rescue analgesics point to the importance of objective measurement tools such as osteoarthritis biomarker panels in long-term glucosamine/chondroitin sulfate clinical trials with less reliance on the subjective measurement tools commonly used in osteoarthritis trials of pharmaceuticals. [Orthopedics. 2018; 41(4):200-207.].
全球范围内,骨关节炎疼痛患者会单独或联合使用氨基葡萄糖和硫酸软骨素。在一些国家,它们需要凭处方购买,但在其他国家,如美国,则可作为非处方膳食补充剂获得。美国国立卫生研究院资助的氨基葡萄糖/软骨素关节炎干预试验(GAIT)结果尚无定论,几乎未能阐明这些药物的疗效。然而,一些较新的研究为它们可能带来的潜在益处提供了更好的视角。由于在GAIT的中重度膝骨关节炎亚组中,二者联合显示出显著的疗效水平,因此本综述考察了从那时至今发表的随机对照试验。这些研究结果不一,部分原因在于,在旨在评估氨基葡萄糖和硫酸软骨素联合使用的缓慢、细微效果的试验方案中,出于伦理考虑加入了救援镇痛药,导致安慰剂反应率较高。安慰剂效应的强大影响以及救援镇痛药对结果的混淆表明,在氨基葡萄糖/硫酸软骨素长期临床试验中,使用骨关节炎生物标志物面板等客观测量工具非常重要,同时减少对骨关节炎药物试验中常用的主观测量工具的依赖。[《骨科》。2018年;41(4):200 - 207。]